AsmitaMishraMD

Physician

Overview of Dr. Mishra

Dr. Asmita Mishra is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from St. George's University School of Medicine and has been in practice 10 years. She is one of 173 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. She has more than 50 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(929) 357-1326

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Louisville School of MedicineResidency, Internal Medicine, 2007 - 2010
St. George's University School of MedicineClass of 2007

Certifications & Licensure

FL State Medical License 2013 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Start of enrollment: 2012 Nov 14
Completed
Phase 1, Phase 2
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2014 Oct 29
Completed
Phase 1
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant Start of enrollment: 2019 Sep 16
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients.
Giacomo Adoncecchi, Ambuj Kumar, Krishnakar Mogili, Rawan Faramand, Hien Liu
Cancers. 2025-01-19
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh
Blood. 2025-01-07
Transplant options and outcomes for TP53 myeloid disease.
Hugo F Fernández, Asmita Mishra
Hematology. American Society of Hematology. Education Program. 2024-12-06

Abstracts/Posters

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
Asmita Mishra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
Asmita Mishra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
Asmita Mishra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
Asmita Mishra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual MeetingDecember 13th, 2021
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual MeetingDecember 13th, 2021
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AMLJuly 21st, 2021
Join now to see all